A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer

  1. Rixe, O.
  2. Franco, S.X.
  3. Yardley, D.A.
  4. Johnston, S.R.
  5. Martin, M.
  6. Arun, B.K.
  7. Letrent, S.P.
  8. Rugo, H.S.
Aldizkaria:
Cancer Chemotherapy and Pharmacology

ISSN: 0344-5704

Argitalpen urtea: 2009

Alea: 64

Zenbakia: 6

Orrialdeak: 1139-1148

Mota: Artikulua

DOI: 10.1007/S00280-009-0975-Z GOOGLE SCHOLAR
Datuen iturria: Scopus